 |
|
Terazosin in the Treatment of Benign Prostatic Hyperplasia
Michael K. Brawer, MD;
George Adams, MD;
Howard Epstein, MD;
the Terazosin Benign Prostatic Hyperplasia Study Group
Arch Fam Med. 1993;2(9):929-935.
Abstract
| |
Objective
To evaluate the efficacy and tolerability of terazosin, a long-acting selective  1-receptor antagonist, in patients with benign prostatic hyperplasia.
Design and Setting
Randomized, double-blind, multicenter (eight government and private facilities), placebo-controlled study.
Patients
Men aged 45 years or older, with qualifying signs and symptoms of benign prostatic hyperplasia (n=160).
Interventions
Terazosin or placebo once daily, with terazosin dosage titrated to the patient's response. After a 4-week placebo lead-in, 1 to 10 mg of terazosin or placebo was administered for 24 weeks.
Outcome Measures
Decreases in mean Boyarsky scores for obstructive and irritative symptoms and total scores and increases in peak urine flow rate.
Results
Terazosin-treated patients had decreases in Boyarsky obstructive, irritative, and total scores of 3.3 (52%), 1.3 (29%), and 4.6 (42%), respectively, compared with decreases of 0.7 (12%), 0.4 (9%), and 1.1 (11%), respectively, in the placebo group (P<.05). Peak urine flow increased by a mean of 2.6 mL/s (30%) in terazosin-treated patients and 1.2 mL/s (14%) in placebo-treated patients (P .05). Adverse events that differed significantly in the two groups were dizziness (19% in the terazosin group vs 5% in the placebo group) and urinary tract infection (1% in the terazosin group vs 10% in the placebo group).
Conclusions
These results suggest that terazosin given once daily in doses up to 10 mg alleviates symptoms and improves peak urine flow rate in men with benign pro-static hyperplasia and has an acceptable adverse event profile.
Author Affiliations
From Veterans Affairs Medical Center, Seattle, Wash (Dr Brawer); Norwood Clinic, Birmingham, Ala (Dr Adams); and Department of Surgery, University of Florida, Gainesville (Dr Epstein). The members of the Terazosin Benign Prostatic Hyperplasia Study Group are listed at the end of this article.
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Use of Meta-analytic Results to Facilitate Shared Decision Making
Lenert and Cher
J. Am. Med. Inform. Assoc. 1999;6:412-419.
ABSTRACT
| FULL TEXT
The Efficacy of Terazosin, Finasteride, or Both in Benign Prostatic Hyperplasia
Lepor et al.
NEJM 1996;335:533-540.
ABSTRACT
| FULL TEXT
Men's Health Issues
Konen
Arch Fam Med 1993;2:917-919.
ABSTRACT
|
